Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;40(2):564-572.
doi: 10.1007/s12640-022-00498-3. Epub 2022 Apr 2.

Protective Effect of CP690550 in MPTP-Induced Parkinson's Like Behavioural, Biochemical and Histological Alterations in Mice

Abdulrahman Alshammari  1 , Metab Alharbi  1 , Norah A Albekairi  1 , Thamer H Albekairi  1 , Omar O Alharbi  1 , Pravin Yeapuri  2 , Sanjiv Singh  3
Affiliations

Protective Effect of CP690550 in MPTP-Induced Parkinson's Like Behavioural, Biochemical and Histological Alterations in Mice

Abdulrahman Alshammari et al. Neurotox Res. 2022 Apr.

Abstract

Janus-activated kinases (JAKs) are well known to play a physiological as well as pathological role in several disease conditions such as autoimmune disorders. The present study evaluated the therapeutic potential of CP690550 (pan-JAK inhibitor) in 1-methyl-4-phenyl-1,2,3,6-tertahydropyridine (MPTP) model of Parkinson's disease. Intrastriatal administration of MPTP (30 micromol in 2 microl) produced a significant alteration in behavioural (bar test and block test). Biochemical investigations in serum and brain homogenate revealed a significant alteration in the JAK-mediated cytokine levels. MPTP administration also showed significant imbalance of inflammatory (increased TNF-α, IL-6 and NF-κb) versus anti-inflammatory cytokines (decreased IL-10 levels). MPTP-treated brain sections revealed alteration in the tissue architecture as well as undifferentiated bodies of varying contour and lesions. Chronic administration of CP690550 (3 and 10 mg/kg, po) for 7 days significantly reversed the behavioural, biochemical and histological alterations induced by MPTP. In conclusion, the findings of the present study govern the possible therapeutic potential of CP690550 in MPTP-treated mice and thus highlight the therapeutic potential of JAK inhibitors in treatment of Parkinson's disease.

Keywords: Astrocytes; Dopaminergic neurons; JAKs; Microglia; Parkinson disease.

PubMed Disclaimer

References

    1. Agid YJTL (1991) Parkinson’s Disease: Pathophysiology 337:1321–1324
    1. Aguirre JA, Leo G, Cueto R, Andbjer B, Naylor A, Medhurst AD, Agnati LF, Fuxe K (2008) The novel cyclooxygenase-2 inhibitor GW637185X protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine toxicity. Neuroreport 19:657–660
    1. Appel SH, Beers DR, Henkel JS (2010) T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol 31(1):7–17
    1. Bartels AL, Leenders KL (2007) Neuroinflammation in the pathophysiology of Parkinson’s disease: evidence from animal models to human in vivo studies with [11C]‐PK11195 PET 22:1852–1856
    1. Benetti F (2012) Gustincich S and Legname GJEoodd. Gene Expression Profiling and Therapeutic Interventions in Neurodegenerative Diseases: a Comprehensive Study on Potentiality and Limits 7:245–259

LinkOut - more resources